JAMP Pharma Group, a leading company in the Canadian pharmaceutical industry for over 35 years, announces today, subject to Superior Court approval and the fulfillment of customary closing conditions, the acquisition of the assets of Pharmalab's manufacturing facility in Lévis, which ceased operations in August 2023.

JAMP Pharma Group，一家在加拿大制药业拥有35年历史的领先公司，今天宣布，根据高等法院的批准和惯例成交条件的满足，收购Pharmalab在莱维斯的制造工厂的资产，该工厂于2023年8月停止运营。

JAMP Pharma Group is proud to acquire and relaunch the manufacturing operations of this plant at a time when governments, customers, and partners are calling for more local procurement solutions. Currently, only 12% of pharmaceutical products consumed by Canadians are made domestically. This acquisition thus strengthens the Canadian supply chain and contributes to addressing drug shortages, an issue that was particularly highlighted during the pandemic.

在政府、客户和合作伙伴呼吁更多当地采购解决方案之际，JAMP Pharma Group很荣幸收购并重新启动该工厂的制造业务。目前，加拿大人消费的药品中只有12%是国内生产的。因此，此次收购加强了加拿大的供应链，有助于解决药物短缺问题，这一问题在大流行期间尤为突出。

'For several years, healthcare professionals and patients have had to deal with inventory shortages. Our ambition was to bolster the local manufacturing capacity to facilitate access to affordable medicine and healthcare solutions. This is a significant milestone for Quebec and Canada. In addition to positively contributing to the creation of wealth in Quebec, JAMP Pharma Group becomes one of the largest Canadian-owned pharmaceutical companies,' said Louis Pilon, President and CEO of JAMP Pharma Group.

“几年来，医疗保健专业人员和患者不得不应对库存短缺。我们的目标是加强当地的制造能力，以便于获得负担得起的药物和医疗保健解决方案。这对魁北克和加拿大来说是一个重要的里程碑。JAMP Pharma Group总裁兼首席执行官路易斯·皮隆（LouisPilon）说，除了为魁北克创造财富做出积极贡献外，JAMP Pharma Group还成为加拿大最大的制药公司之一。

The company plans to make substantial investments in research and development to bring new product formulations to market and ensure the continuous supply of several new generic products. This acquisition will enable the company to repatriate the production of tablets, capsules, oral liquids, and oral powders to Canada.

该公司计划在研发方面进行大量投资，将新产品配方推向市场，并确保持续供应几种新的仿制药。此次收购将使该公司能够将片剂、胶囊、口服液和口服粉的生产退回加拿大。

This production autonomy will allow JAMP Pharma Group to enhance its level of service to its customers and partners while ensuring continuity in patient treatments.

这种生产自主权将使JAMP Pharma Group能够提高其对客户和合作伙伴的服务水平，同时确保患者治疗的连续性。

The integration of the plant - spanning over 100,000 square feet - into JAMP Pharma Group's operations will be gradual. An assessment of the facilities and equipment will be conducted to ensure the plant meets the highest industry standards. The need for skilled labour will also be studied; JAMP Pharma Group aims to hire a significant portion of the 250 former Pharmalab employees, adding them to its current workforce of over 700 employees.

该工厂占地面积超过10万平方英尺，将逐步整合到JAMP制药集团的运营中。将对设施和设备进行评估，以确保工厂符合最高行业标准。还将研究对熟练劳动力的需求；JAMP Pharma Group的目标是在250名前Pharmalab员工中雇佣一大部分，将他们增加到现有的700多名员工中。

JAMP Pharma Group would like to take this opportunity to sincerely thank its partners, employees, customers, as well as the Fonds de solidarité FTQ, a partner of JAMP Pharma Group. Thanks to them, JAMP Pharma Group can continue dedicating itself to creating a brighter healthier future for all, one patient and one customer at a time.

JAMP Pharma Group借此机会衷心感谢其合作伙伴、员工、客户以及JAMP Pharma Group的合作伙伴Fonds de solidaritéFTQ。多亏了他们，JAMP制药集团可以继续致力于为所有人，一次一个病人和一个客户创造一个更光明更健康的未来。

'This recent acquisition by JAMP Pharma Group demonstrates its leadership in the Canadian generic drug industry and its commitment to the economic development of Quebec. Fonds de solidarité FTQ is proud to have supported the growth of this Canadian flagship since 2016 and continues to support the company in its future endeavours,' said Patrice Jolivet, Vice-President, Investments - Agri-Food and Health at Fonds de solidarité FTQ.

“JAMP Pharma Group最近的收购证明了其在加拿大仿制药行业的领导地位以及对魁北克经济发展的承诺。solidaritéFTQ基金会农业食品与健康投资副总裁帕特里斯·乔利维特（PatriceJolivet）表示，自2016年以来，该基金会一直支持这家加拿大旗舰店的发展，并将继续支持该公司未来的努力，我们对此感到骄傲。

About JAMP Pharma Group

关于JAMP Pharma Group

JAMP Pharma Group is a Canadian organization headquartered in Boucherville, in the greater Montreal area. Having experienced exceptional growth over the past 10 years, JAMP Pharma Group is present in all segments of the pharmaceutical market with a portfolio of over 325 molecules and is one of the industry leaders in terms of annual prescription volume1.

JAMP Pharma Group是一家加拿大组织，总部位于大蒙特利尔地区的Boucherville。JAMP Pharma Group在过去10年中经历了非凡的增长，目前已进入制药市场的各个领域，拥有超过325个分子的投资组合，并且是年度处方量方面的行业领导者之一1。

With over 130 new products authorized for sale by Health Canada in the past three years, JAMP Pharma Group is the Canadian leader in product launches2, thereby constantly providing new and improved treatment options for Canadians, including many specialty drugs. The addition of a new local manufacturing site supports JAMP Pharma Group's vision of becoming the largest Canadian-owned pharmaceutical company.

在过去三年中，加拿大卫生部批准销售130多种新产品，JAMP Pharma Group是加拿大产品发布的领导者2，因此不断为加拿大人提供新的和改进的治疗选择，包括许多特殊药物。增加一个新的当地生产基地支持了JAMP Pharma Group成为加拿大最大的制药公司的愿景。

In addition to its generic division, JAMP Pharma Group owns several divisions such as Orimed, BioJAMP, Wampole, Laboratoire Suisse, and Cosmetic Import, also offering prescription and branded products, biosimilars, and 180 over-the-counter products, as well as a varied range of vitamins, supplements, and natural health products.

除仿制药部门外，JAMP Pharma Group还拥有Orimed、BioJAMP、Wampole、Laboratoire Suisse和化妆品进口等多个部门，还提供处方和品牌产品、生物仿制药和180种非处方产品，以及各种维生素、补充剂和天然保健品。

The JAMP CareMC patient support program is designed to assist both patients, and healthcare professionals in the use of specialty drugs and biosimilars offered by JAMP Pharma Group.

JAMP CareMC患者支持计划旨在帮助患者和医疗保健专业人员使用JAMP Pharma Group提供的特殊药物和生物仿制药。